Mobile App for Improving Adherence of Rivoxaban (RIVOX-AF)

Seoul National University

Status: Enrolling

Conditions: Atrial Fibrillation

Treatments: Device: MEDI-app

Study type: Interventional

Funder types: Other

Identifiers

NCT05557123

RIVOX-AF

Details and patient eligibility

About

RIVOX-AF study is a prospective, multicenter, randomized controlled study in which patients with AF are allocated to medication-app group or conventional treatment group. The App based feed-back algorithm will provide the patients with check taking drug or reminding of taking drug.

Enrollment: 1,042 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with AF aged 19 years or older with one or more comorbidities including heart failure, myocardial infarction, stable angina, hypertension or diabetes mellitus (Patients can be enrolled 3 months after myocardial infarction or percutaneous coronary intervention).
• patients who already took or plan to take rivoxban
• patients who able to use smart phone

Exclusion criteria

• creatinine clearance <15ml/min
• moderate or severe mitral stenosis
• mitral valve operation history
• current alcohol abuse or alcohol abus history
• Not eligible for study due to legal or psychiatric problem
• enrolled other clinical study within 4 weeks
• declined to enroll the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

1,042 participants in 2 patient groups

MEDI-app

Experimental group

Description:

conventional treatment with MEDI-app feedback

Treatment:

Device: MEDI-app

conventional treatment

No Intervention group

Description:

conventional treatment